As part of its advocacy program in the United States, ACRO submits regulatory comments to US regulators. This comment letter, submitted by ACRO to FDA in 2015 about Use of Electronic Informed Consent in Clinical Investigations: Questions and Answers – Draft Guidance can be found below.